Search

Your search keyword '"Soria, Angèle"' showing total 350 results

Search Constraints

Start Over You searched for: Author "Soria, Angèle" Remove constraint Author: "Soria, Angèle" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
350 results on '"Soria, Angèle"'

Search Results

1. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

3. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

4. Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study

5. In Situ Patch Test and Repeated Open Application Test for Fixed Drug Eruption: A Multicenter Study

6. Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes

7. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study

8. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study

9. Successful treatment of JAK1-associated inflammatory disease

11. Pholcodine exposure increases the risk of perioperative anaphylaxis to neuromuscular blocking agents: the ALPHO case-control study

15. Cholinergic pruritus treated with omalizumab: Seven cases

16. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

19. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

22. Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study

23. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

24. Does adipose tissue contribute to acute infection-related inflammation in COVID-19?

25. Pholcodine exposure increases the risk of perioperative anaphylaxis to neuromuscular blocking agents: the ALPHO case-control study

26. Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis

27. The immunological effects of intradermal particle-based vaccine delivery using a novel microinjection needle studied in a human skin explant model

28. Guidelines for cold urticaria management established by the Centre of Evidence of Dermatology and the Urticaria Group of the French Society of Dermatology.

29. Risk stratification through extensive allergy work‐up in COVID‐19‐mRNA vaccine allergic reactions

30. In SituPatch Test and Repeated Open Application Test for Fixed Drug Eruption: A Multicenter Study

32. Allergic contact dermatitis from essential oil in consumer products: Mode of uses and value of patch tests with an essential oil series. Results of a French study of the DAG (Dermato‐Allergology group of the French Society of Dermatology).

33. Intravenous and subcutaneous immunoglobulins-associated eczematous reactions occur with a broad range of immunoglobulin types: A French national multicenter study

34. A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial – the PRADA trial

35. Systemic inflammatory trunk recurrent acute macular eruption ( SITRAME ): A new auto‐inflammatory syndrome in adult?

36. Chemical characterization of inks in skin reactions to tattoo

37. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort

39. Discrepancies in the management of acquired cold contact urticaria: Results of a French-speaking urticaria experts questionnaire survey

41. Allergic contact dermatitis caused by PEG‐22 and PEG‐45 dodecyl glycol copolymers in two skin‐repairing creams.

42. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

45. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort.

48. Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper

Catalog

Books, media, physical & digital resources